治療用血漿交換のアメリカ市場予測(〜2025):製品物(デバイス、消耗品)、技術別(遠心分離、膜分離)、処置・患者別(ギラン症候群、多発性硬化症、クリオグロブリン血症)、エンドユーザー別、新型コロナウイルス感染症の影響

◆英語タイトル:US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users Covid-19 Impact - Forecast to 2025
◆商品コード:MD 4451
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年9月24日
◆ページ数:122
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アメリカ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Marketsandmarkets社は治療用血漿交換のアメリカ市場が2020年178百万ドルから2025年243百万ドルまで、年平均6.3%成長すると展望しています。本調査レポートでは、治療用血漿交換のアメリカ市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・技術別分析、疾患別分析、エンドユーザー別分析、競争状況、企業情報など、以下の構成でお届けいたします。
【レポートの概要】

“The US therapeutic plasma exchange market is projected to reach USD 243 million by 2025 from USD 178 million in 2020, at a CAGR of 6.3% during the forecast period.” Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.
“The consumables segment to grow at the highest rate during the forecast period.”
On the basis of products, the US therapeutic plasma exchange market has been segmented into devices and consumables. The consumables segment witness the highest growth during the forecast period. The large share of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.

“Advantages offered by centrifugation over membrane separation are driving market growth for centrifugation.”
On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. In 2019, the centrifugation technology segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components.

“Blood collection centers and blood component providers accounted for the largest share of the end user market “
On the basis of end user, the US therapeutic plasma exchange market has been segmented into blood
collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2019, the blood collection centers and blood component providers segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, the growing number of blood centers, and the increasing number of therapeutic plasma exchange procedures and plasma donations due to COVID-19.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–30%, Tier 2–45%, and Tier 3–25%
• By Designation: C-level–35%, Director Level–25%, and Others–40%

The prominent players in the US therapeutic plasma exchange market include Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland).

Research Coverage:
The report analyzes the market for various US therapeutic plasma exchange and their adoption pattern. It aims at estimating the market size and future growth potential of the US therapeutic plasma exchange market and different segments such as products, end user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the US therapeutic plasma exchange market
• Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the US therapeutic plasma exchange market
• Market Development: Comprehensive information on the lucrative emerging regions by products, technology, indication, and end user
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the US therapeutic plasma exchange market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the US therapeutic plasma exchange market

【レポートの目次】

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.2.1 INCLUSIONS AND EXCLUSIONS 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 20
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20
1.7 SUMMARY OF CHANGES 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
FIGURE 1 RESEARCH DESIGN 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY DATA 24
FIGURE 2 PRIMARY SOURCES 24
2.1.2.1 Key data from primary sources 25
2.1.2.2 Breakdown of primary interviews 25
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY
TYPE AND DESIGNATION 25
2.2 MARKET SIZE ESTIMATION 26
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 26
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (ILLUSTRATIVE EXAMPLE) 27
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 28
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 30
FIGURE 7 DATA TRIANGULATION METHODOLOGY 30
2.4 MARKET SHARE ESTIMATION 31
2.5 ASSUMPTIONS FOR THE STUDY 31
3 EXECUTIVE SUMMARY 32
FIGURE 8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 32
FIGURE 9 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY,
2020 VS. 2025 (USD MILLION) 33
FIGURE 10 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION,
2020 VS. 2025 (USD MILLION) 33
FIGURE 11 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 34
4 MARKET OVERVIEW 35
4.1 INTRODUCTION 35
4.2 MARKET DYNAMICS 35
FIGURE 12 US THERAPEUTIC PLASMA EXCHANGE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
4.2.1 DRIVERS 36
4.2.1.1 Rising prevalence of chronic diseases 36
4.2.1.2 Technological advancements 36
4.2.2 RESTRAINTS 37
4.2.2.1 High cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model 37
4.2.3 OPPORTUNITIES 37
4.2.3.1 Therapeutic plasma exchange for pediatric patients 37
4.2.4 CHALLENGES 38
4.2.4.1 Dearth of skilled professionals 38
5 INDUSTRY INSIGHTS 39
5.1 INDUSTRY TRENDS 39
5.1.1 IMPACT OF COVID-19 ON THE THERAPEUTIC PLASMA EXCHANGE MARKET 39
FIGURE 13 IMPACT OF COVID-19 (2020-2025) 40
5.1.2 NEW INDICATIONS FOR PLASMA PRODUCTS 40
5.2 PORTER’S FIVE FORCES ANALYSIS 41
FIGURE 14 PORTER’S FIVE FORCES ANALYSIS (2019): US THERAPEUTIC PLASMA EXCHANGE MARKET 41
5.2.1 THREAT OF NEW ENTRANTS 42
5.2.2 THREAT OF SUBSTITUTES 42
5.2.3 BARGAINING POWER OF SUPPLIERS 42
5.2.4 BARGAINING POWER OF BUYERS 43
5.2.5 RIVALRY AMONG EXISTING COMPETITORS 43
5.3 VALUE CHAIN ANALYSIS 43
FIGURE 15 VALUE CHAIN: US THERAPEUTIC PLASMA EXCHANGE MARKET 44
5.4 REGULATORY ANALYSIS 45
5.4.1 US 45

6 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT & TECHNOLOGY 46
6.1 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT 47
6.1.1 INTRODUCTION 47
TABLE 2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 47
6.1.2 CONSUMABLES 47
6.1.2.1 Recurrent use of consumables to drive the growth of this segment 47
6.1.3 DEVICES 48
6.1.3.1 Increasing installation of devices in hospitals for therapeutic plasma exchange to drive market growth 48
6.2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY 49
6.2.1 INTRODUCTION 49
TABLE 3 CENTRIFUGATION VS. MEMBRANE SEPARATION 49
FIGURE 16 CENTRIFUGATION SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD 49
TABLE 4 THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 50
6.2.2 CENTRIFUGATION 50
6.2.2.1 Centrifugation technology to dominate the US therapeutic plasma exchange market 50
TABLE 5 KEY PRODUCTS OFFERED IN THE CENTRIFUGATION MARKET 50
6.2.3 MEMBRANE SEPARATION 51
6.2.3.1 Recent advances in developing highly permeable filters are supporting the growth of this market 51
TABLE 6 SIZE OF BLOOD COMPONENTS 51
TABLE 7 MEMBRANE SEPARATION PRODUCTS AVAILABLE IN THE MARKET 52
7 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION 53
7.1 INTRODUCTION 54
7.2 NEUROLOGICAL DISORDERS 54
7.2.1 NEUROLOGICAL DISORDERS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019 54
TABLE 8 NEUROLOGICAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 54
7.2.1.1 Guillain–Barré syndrome 55
7.2.1.1.1 Patient and procedure data for guillain-barré syndrome 55
TABLE 9 DISEASE STATISTICS: GUILLAIN-BARRÉ SYNDROME 55
TABLE 10 TREATMENT GUIDELINES AND PROTOCOLS FOR GUILLAIN-BARRÉ SYNDROME 55
TABLE 11 EPIDEMIOLOGY FOR GUILLAIN-BARRÉ SYNDROME 56
7.2.1.2 Chronic inflammatory demyelinating polyneuropathy 56
7.2.1.2.1 Patient and procedure data for chronic inflammatory demyelinating polyneuropathy 56
TABLE 12 DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY 56
TABLE 13 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY 57
TABLE 14 EPIDEMIOLOGY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY 57
7.2.1.3 Myasthenia gravis 57
7.2.1.3.1 Patient and procedure data for myasthenia gravis 58
TABLE 15 DISEASE STATISTICS: MYASTHENIA GRAVIS 58
TABLE 16 TREATMENT GUIDELINES AND PROTOCOLS FOR MYASTHENIA GRAVIS 58
TABLE 17 EPIDEMIOLOGY FOR MYASTHENIA GRAVIS 59
7.2.1.4 Multiple sclerosis 59
7.2.1.4.1 Patient and procedure data for multiple sclerosis 59
TABLE 18 DISEASE STATISTICS: MULTIPLE SCLEROSIS 59
TABLE 19 TREATMENT GUIDELINES AND PROTOCOLS FOR MULTIPLE SCLEROSIS 60
TABLE 20 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS 60
TABLE 21 EPIDEMIOLOGY FOR MULTIPLE SCLEROSIS 60
7.2.1.5 PANDAS 61
7.2.1.5.1 Patient and procedure data for PANDAS 61
TABLE 22 DISEASE STATISTICS: PANDAS 61
TABLE 23 TREATMENT GUIDELINES AND PROTOCOLS FOR PANDAS 61
TABLE 24 EPIDEMIOLOGY FOR PANDAS 62
7.3 HEMATOLOGIC DISORDERS 62
7.3.1 INCREASING PREVALENCE AND INCIDENCE OF HEMATOLOGIC DISORDERS WILL BOOST THE DEMAND FOR THERAPEUTIC PLASMA EXCHANGE 62
TABLE 25 HEMATOLOGIC DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 62
7.3.1.1 Thrombotic thrombocytopenic purpura 62
7.3.1.1.1 Patient and procedure data for thrombotic thrombocytopenic purpura 63
TABLE 26 DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA 63
TABLE 27 TREATMENT GUIDELINES AND PROTOCOLS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA 63
TABLE 28 EPIDEMIOLOGY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA 63
7.3.1.2 Atypical hemolytic uremic syndrome 64
7.3.1.2.1 Patient and procedure data for atypical hemolytic uremic syndrome 64
TABLE 29 DISEASE STATISTICS: ATYPICAL HEMOLYTIC UREMIC SYNDROME 64
TABLE 30 TREATMENT GUIDELINES AND PROTOCOL FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME 65
TABLE 31 EPIDEMIOLOGY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME 65
7.3.1.3 Hyperviscosity syndrome 65
7.3.1.3.1 Patient and procedure data for hyperviscosity syndrome 66
TABLE 32 DISEASE STATISTICS: HYPERVISCOSITY SYNDROME 66
TABLE 33 TREATMENT GUIDELINES AND PROTOCOLS FOR HYPERVISCOSITY SYNDROME 66
TABLE 34 EPIDEMIOLOGY FOR HYPERVISCOSITY SYNDROME 66
7.3.1.4 Severe/symptomatic cryoglobulinemia 67
7.3.1.4.1 Patient and procedure data for cryoglobulinemia 67
TABLE 35 DISEASE STATISTICS: CRYOGLOBULINEMIA 67
TABLE 36 TREATMENT GUIDELINES AND PROTOCOLS FOR CRYOGLOBULINEMIA 67
TABLE 37 EPIDEMIOLOGY FOR CRYOGLOBULINEMIA 68
7.4 RENAL DISORDERS 68
7.4.1 THERAPEUTIC PLASMA EXCHANGE IS REGARDED AS ONE OF THE MOST USEFUL TREATMENT OPTIONS FOR SEVERAL RENAL DISORDERS 68
TABLE 38 RENAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 68
7.4.1.1 Goodpasture syndrome 69
7.4.1.1.1 Patient and procedure data for goodpasture syndrome 69
TABLE 39 DISEASE STATISTICS: GOODPASTURE SYNDROME 69
TABLE 40 TREATMENT GUIDELINES AND PROTOCOLS FOR GOODPASTURE SYNDROME 69
TABLE 41 EPIDEMIOLOGY FOR GOODPASTURE SYNDROME 70
7.4.1.2 WEGENER’S GRANULOMATOSIS (ANCA)-associated rapidly progressive glomerulonephritis 70
7.4.1.2.1 Patient and procedure data for wegener’s granulomatosis 70
TABLE 42 DISEASE STATISTICS: WEGENER’S GRANULOMATOSIS 70
TABLE 43 TREATMENT GUIDELINES AND PROTOCOLS FOR WEGENER’S GRANULOMATOSIS 71
TABLE 44 EPIDEMIOLOGY FOR WEGENER’S GRANULOMATOSIS 71
7.4.1.3 Antibody-mediated renal transplant rejection 71
7.4.1.3.1 Patient and procedure data for AMR 72
TABLE 45 DISEASE STATISTICS: ANTIBODY‐MEDIATED REJECTION 72
TABLE 46 TREATMENT GUIDELINES AND PROTOCOLS FOR ANTIBODY‐MEDIATED REJECTION 72
TABLE 47 EPIDEMIOLOGY FOR ANTIBODY‐MEDIATED REJECTION 72
7.5 METABOLIC DISORDERS 73
7.5.1 INCREASING ADOPTION OF PLASMA EXCHANGE FOR DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH 73
7.5.1.1 Familial hypercholesterolemia (homozygous) 73
7.5.1.1.1 Patient and procedure data for homozygous familial hypercholesterolemia 73
TABLE 48 DISEASE STATISTICS: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 73
TABLE 49 TREATMENT GUIDELINES AND PROTOCOLS FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 74
TABLE 50 EPIDEMIOLOGY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 74
7.6 OTHER INDICATIONS 74

8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER 75
8.1 INTRODUCTION 76
FIGURE 17 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD 76
TABLE 51 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER,
2018–2025 (USD MILLION) 76
8.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS 77
8.2.1 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS ARE THE LARGEST END USERS OF THERAPEUTIC PLASMA EXCHANGE 77
FIGURE 18 NUMBER OF ANNUAL PLASMA DONATIONS IN THE US,
2003−2016 (MILLION) 77
8.3 HOSPITALS & TRANSFUSION CENTERS 78
8.3.1 HOSPITALS & TRANSFUSION CENTERS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 78
8.4 OTHER END USERS 78
9 COMPETITIVE LANDSCAPE 79
9.1 OVERVIEW 79
FIGURE 19 KEY DEVELOPMENTS IN THE US THERAPEUTIC PLASMA EXCHANGE MARKET, JANUARY 2017−JULY 2020 79
9.2 MARKET EVALUATION FRAMEWORK 80
FIGURE 20 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES & APPROVALS WERE THE MOST WIDELY ADOPTED STRATEGIES 80
9.3 COMPETITIVE SITUATIONS AND TRENDS 80
9.3.1 PRODUCT LAUNCHES & APPROVALS 80
9.3.2 EXPANSIONS 81
9.3.3 ACQUISITIONS 82
9.3.4 COLLABORATIONS 82
10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 83
10.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY 83
10.2 COMPETITIVE LEADERSHIP MAPPING 83
10.2.1 STARS 83
10.2.2 EMERGING LEADERS 83
10.2.3 PERVASIVE 84
10.2.4 EMERGING COMPANIES 84
FIGURE 21 US THERAPEUTIC PLASMA EXCHANGE MARKET: COMPETITIVE LEADERSHIP MAPPING (2019) 84
10.3 MARKET SHARE ANALYSIS 85
FIGURE 22 US THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2019 85

10.4 COMPANY PROFILES 87
(Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View)*
10.4.1 TERUMO BCT, INC. 87
FIGURE 23 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018) 87
10.4.2 FRESENIUS SE & CO. KGAA 90
FIGURE 24 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019) 90
FIGURE 25 FRESENIUS KABI: COMPANY SNAPSHOT (2019) 91
10.4.3 HAEMONETICS CORPORATION 94
FIGURE 26 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2020) 94
10.4.4 BAXTER INTERNATIONAL INC. 97
FIGURE 27 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2019) 97
10.4.5 ASAHI KASEI MEDICAL CO. LTD. 100
FIGURE 28 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019) 100
10.4.6 B. BRAUN MELSUNGEN AG 103
FIGURE 29 B. BRAUN MELSUNGEN: COMPANY SNAPSHOT (2019) 103
10.4.7 CERUS CORPORATION 105
FIGURE 30 CERUS CORPORATION: COMPANY SNAPSHOT (2019) 105
10.4.8 KANEKA CORPORATION 107
FIGURE 31 KANEKA CORPORATION: COMPANY SNAPSHOT (2019) 107
10.4.9 KAWASUMI LABORATORIES, INC. 109
FIGURE 32 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019) 109
10.4.10 NIKKISO CO., LTD. 110
FIGURE 33 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2019) 110
10.4.11 MILTENYI BIOTEC 112
10.4.12 MEDICA S.P.A. 113
10.4.13 MEDICAP CLINIC GMBH 114
10.4.14 INFOMED 115
*Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX 116
11.1 INSIGHTS OF INDUSTRY EXPERTS 116
11.2 DISCUSSION GUIDE 117
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 120
11.4 AVAILABLE CUSTOMIZATIONS 122
11.5 RELATED REPORTS 122
11.6 AUTHOR DETAILS 123



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[治療用血漿交換のアメリカ市場予測(〜2025):製品物(デバイス、消耗品)、技術別(遠心分離、膜分離)、処置・患者別(ギラン症候群、多発性硬化症、クリオグロブリン血症)、エンドユーザー別、新型コロナウイルス感染症の影響]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆